Leonid Timashev
Stock Analyst at RBC Capital
(1.91)
# 3,090
Out of 4,944 analysts
103
Total ratings
36.56%
Success rate
-9.73%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Outperform | $75 → $77 | $37.15 | +107.27% | 13 | Aug 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $12 → $13 | $8.42 | +54.39% | 2 | Aug 8, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $6 → $7 | $2.49 | +181.12% | 2 | Aug 8, 2025 | |
| INSM Insmed | Maintains: Outperform | $108 → $120 | $122.57 | -2.10% | 4 | Aug 8, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $48 → $49 | $13.71 | +257.40% | 14 | Aug 8, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $38 → $39 | $25.08 | +55.50% | 7 | Aug 7, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $349 → $364 | $300.35 | +21.19% | 3 | Aug 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $184 → $189 | $108.31 | +74.51% | 13 | Aug 5, 2025 | |
| ALKS Alkermes | Maintains: Sector Perform | $40 → $42 | $28.10 | +49.47% | 3 | Jul 30, 2025 | |
| EXEL Exelixis | Maintains: Sector Perform | $50 → $45 | $38.25 | +17.65% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $25 | $7.75 | +222.58% | 1 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $53 | $25.27 | +109.73% | 1 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $30 | $24.07 | +24.64% | 1 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 → $17 | $12.15 | +39.92% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.13 | +60.00% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $3.93 | +307.12% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $54 → $21 | $13.93 | +50.75% | 12 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $80 | $35.61 | +124.66% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.07 | +647.66% | 6 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.53 | +96.72% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $83.75 | -16.42% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $4.41 | +308.16% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $5.09 | -21.41% | 8 | Aug 6, 2024 |
Legend Biotech
Aug 12, 2025
Maintains: Outperform
Price Target: $75 → $77
Current: $37.15
Upside: +107.27%
Verastem
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $8.42
Upside: +54.39%
Nuvation Bio
Aug 8, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $2.49
Upside: +181.12%
Insmed
Aug 8, 2025
Maintains: Outperform
Price Target: $108 → $120
Current: $122.57
Upside: -2.10%
Edgewise Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $48 → $49
Current: $13.71
Upside: +257.40%
NewAmsterdam Pharma Company
Aug 7, 2025
Maintains: Outperform
Price Target: $38 → $39
Current: $25.08
Upside: +55.50%
BeOne Medicines
Aug 7, 2025
Maintains: Outperform
Price Target: $349 → $364
Current: $300.35
Upside: +21.19%
Axsome Therapeutics
Aug 5, 2025
Maintains: Outperform
Price Target: $184 → $189
Current: $108.31
Upside: +74.51%
Alkermes
Jul 30, 2025
Maintains: Sector Perform
Price Target: $40 → $42
Current: $28.10
Upside: +49.47%
Exelixis
Jul 29, 2025
Maintains: Sector Perform
Price Target: $50 → $45
Current: $38.25
Upside: +17.65%
Jul 17, 2025
Maintains: Outperform
Price Target: $32 → $25
Current: $7.75
Upside: +222.58%
Jul 16, 2025
Maintains: Outperform
Price Target: $68 → $53
Current: $25.27
Upside: +109.73%
Jul 9, 2025
Maintains: Outperform
Price Target: $57 → $30
Current: $24.07
Upside: +24.64%
Jun 20, 2025
Reiterates: Outperform
Price Target: $13 → $17
Current: $12.15
Upside: +39.92%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.13
Upside: +60.00%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $3.93
Upside: +307.12%
May 19, 2025
Downgrades: Sector Perform
Price Target: $54 → $21
Current: $13.93
Upside: +50.75%
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $35.61
Upside: +124.66%
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.07
Upside: +647.66%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.53
Upside: +96.72%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $83.75
Upside: -16.42%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $4.41
Upside: +308.16%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $5.09
Upside: -21.41%